+ Watch CLVS
on My Watchlist
CLVS BUY@45 TP 83
Negative side affects to it's primary experimental cancer drug, burning through cash, can't find a buyer
I'll play this game of shorts, now on the long side.
Pharma stock recommended by Dr. Yaron Werber citi researchLung cancer drugPlus two other drugs
No revenue yet...
Buyers are not interested at unjustified market cap valuation. sell and take the profits a great short sell now.
Pipeline doesn't justify $2.2 billion valuation.
IBD EPS, RS, SPROE, Acc ratings plus P/E and div yieldMEDICAL 5 95 -B+ NO EARN
400M isn't an outrageous market cap for a company with 163M in cash and two early stage oncology candidates. The thing is, Clovis had the same valuation in August when topline results of their pivotal trial of their lead oncology candidate were still pending. Even though the share price ran up ahead of the crash when the trial failed and development of the lead candidate was terminated, it doesn't make sense for the stock to be running up again so quickly. I think the street is still showing overconfidence in this management team.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions